For research purposes only — not for human consumption — 18+ only

Retatrutide 20mg

$150.00

Higher-dose Retatrutide for advanced metabolic research.

SKU: RT20 Category:

Reviews

There are no reviews yet.

Be the first to review “Retatrutide 20mg”

Your email address will not be published. Required fields are marked *

Retatrutide 20mg — higher-dose vial of LY3437943, Eli Lilly's next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This vial provides sufficient compound for extended or multi-arm research protocols. Retatrutide represents the leading edge of metabolic peptide pharmacology, with Phase II trials demonstrating average weight reduction of 24.2% at 48 weeks — results that exceed all previously available compounds in this class.

Molecular Data

Molecular Formula: C187H291N45O57 | Molecular Weight: 4130.6 g/mol | CAS Number: 2381606-29-3

Triple Receptor Mechanism

Acts simultaneously on GLP-1, GIP (at 8.9× endogenous potency), and glucagon receptors — producing synergistic effects on appetite suppression, insulin sensitivity, and metabolic rate through three independent pathways. The glucagon receptor component drives energy expenditure through thermogenesis, a mechanism absent in semaglutide and tirzepatide.

Phase II Clinical Results

Participants receiving 12mg weekly achieved mean weight loss of 17.5% at 24 weeks and 24.2% at 48 weeks. Secondary outcomes included improvements in triglycerides, HDL, blood pressure, fasting glucose, and liver fat content (MASLD sub-study). Phase III TRIUMPH trials are currently ongoing.

Extended Research Applications

The 20mg vial is designed for research protocols requiring larger quantities — including dose-response studies, multi-arm comparisons, or longer-duration animal model experiments. The fatty diacid modification provides a ~6-day half-life enabling weekly dosing schedules.

Future Research

Currently in Phase III TRIUMPH trials. Research interest includes obesity, type 2 diabetes, MASLD, cardiovascular risk, and kidney disease models.

Scroll to Top